GeneDx Holdings Corp. (WGS)
About GeneDx Holdings Corp.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $427.5M
- Net income
- -$21.0M
- Total assets
- $523.7M
- Market cap
- $1.8B
- Gross margin
- 69.7%
- Operating margin
- -3.1%
- Net margin
- -4.9%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $427.5M
- Cost of revenue
- $129.4M
- Gross profit
- $298.2M
- Operating expenses
- $311.2M
- Operating income
- -$13.1M
- Income tax
- -$116.0K
- Net income
- -$21.0M
- EPS (basic)
- $-0.73
- EPS (diluted)
- $-0.73
Balance sheet
- Total assets
- $523.7M
- Current assets
- $268.3M
- Total liabilities
- $215.5M
- Current liabilities
- $108.9M
- Shareholders’ equity
- $308.2M
Cash flow
- Operating cash flow
- $33.3M
- Investing cash flow
- -$61.5M
- Financing cash flow
- $48.0M
- Net cash flow
- $19.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.8B
- EPS (diluted)
- $-0.73
- Shares outstanding
- 19.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2021
GeneDx Holdings Corp. (WGS) Stock Price
- Reported a net loss of $21.0M in FY2025.
- Revenue grew 111% from FY2023 to FY2025.
- Gross margin of 69.7%, net margin -4.9%.
- Trading 47% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GeneDx Holdings Corp..
Write a review
News about GeneDx Holdings Corp.
News & sentiment via Polygon.io
GeneDx Holdings Corp.: frequently asked questions
Is GeneDx Holdings Corp. an American company?
GeneDx Holdings Corp. is a US-based company headquartered in Stamford, Connecticut, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is GeneDx Holdings Corp. headquartered?
GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States.
Is GeneDx Holdings Corp. publicly traded?
Yes — GeneDx Holdings Corp. is a publicly traded company. Its stock trades under the ticker symbol WGS on the NASDAQ.
What does GeneDx Holdings Corp. do?
GeneDx Holdings Corp. is an American Medical Devices company in the Health & Beauty sector.
